Navigation Links
DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
Date:1/29/2009

EVRY, France, January 29 /PRNewswire/ -- DNA Therapeutics, an emerging biopharmaceutical company specialized in the development of innovat0ive medicines in oncology, announces the successful closing of its Series A equity investment round. The investor syndicate led by SGAM SEFTI with two of the previous seed investors, Blue Medical Investments and G1J-Ile de France, is committed to invest 2.2 million EUR based on certain milestones to be met. Since June 2008, DNA Therapeutics has raised 3 million EUR (US$4 million) through the current Series A and the previous seed financing round led by Inserm-Transfert Initiative.

The funds will enable DNA Therapeutics to advance the vectorization and the additional proofs of concept, and to achieve regulatory preclinical studies of its lead product, named Dbait. DNA Therapeutics is developing a new class of drugs fighting tumor resistance to conventional therapies. In current cancer treatment, the effectiveness of radiotherapy and chemotherapy are often limited by the action of DNA repair processes on the damages caused by these therapies. The innovative aspect of siDNA (signal interfering DNA) technology developed in DNA Therapeutics is to use a short fragment of DNA, a mimetic of DNA damage, to interfere with the sensing and signaling of DNA damages in the nucleus, and ultimately, inhibit their repair during the treatment period. Thus siDNA increases the effectiveness of radiotherapy and chemotherapy without adding any cytotoxic effect. The company possesses a portfolio of exclusive worldwide licenses resulting from the pioneering work of its founding scientists at the Institut Curie, the CNRS, the INSERM (French NIH) and the French National Museum of Natural History.

Prof. Jian-Sheng Sun, co-founder, Chairman and CEO commented: "We are delighted to have received this significant investment from SGAM SEFTI that is strongly committed to support Life Science innovati
'/>"/>

SOURCE DNA Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
2. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
3. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
4. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
5. Cephalon Signs Option Agreement to Acquire Ception Therapeutics
6. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
7. Cara Therapeutics Initiates Phase II Proof-Of-Concept Trial of Novel Analgesic in Acute Post-Operative Pain
8. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
9. Synvista Therapeutics Announces Published Data Demonstrating Elevation of Carboxymethyl-Lysine (CML) Is Associated with Decline in Renal Function and Arterial Stiffness in Older Adults
10. Synvista Therapeutics Announces First Dosing of SYI-2074 in Clinical Trial for Psoriasis
11. Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 1, 2014 Research and Markets ... "Global Medical Biosensors Market 2014-2018" report to ... Medical biosensors are used to ... detectors. These biosensors monitor health status, disease betterment, ... methods. They are cost-effective and user-friendly devices. Also, ...
(Date:8/1/2014)... 1, 2014  NxStage Medical, Inc. (Nasdaq: NXTM ... that Jeffrey H. Burbank , Chief Executive Officer, and ... the 34 th Annual Canaccord Genuity Growth Conference being ... , on Wednesday, August 13 th at 4:30 p.m. ... at http://ir.nxstage.com/ .  About NxStage Medical ...
(Date:8/1/2014)... 2014 Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... are used to develop, manufacture and sell enzymes and ... industrial enzyme industries, announced today that it will report ... 30, 2014 after market close on Thursday, August 14, ... at 5:00 p.m. Eastern Time to discuss those results. ...
Breaking Medicine Technology:Global Medical Biosensors Market 2014-2018: Key Vendors are Abbott, Bayer, LifeScan and F. Hoffmann-La Roche 2NxStage to Present at the 34th Annual Canaccord Genuity Growth Conference 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 2Dyadic International To Announce Second Quarter 2014 Financial Results And Host Conference Call On Thursday, August 14, 2014 3
... Alere Inc. (NYSE: ALR ) ("Alere") announced ... totaling $2.1 billion.  Jefferies Finance LLC, GE Capital Markets, ... as joint lead arrangers for the credit facilities, and ... for the lenders under the credit facilities. ...
... Qmed.com , a UBM Canon publishing group brand ... directory and search engine, announced its supplier profiles are ... websites. This new search functionality allows medical device professionals ... paid listings) in search results when they conduct keyword ...
Cached Medicine Technology:Alere Inc. Announces $2.1 Billion Credit Facilities 2Qmed Profiles Searchable Across All Medical Device Websites 2Qmed Profiles Searchable Across All Medical Device Websites 3
(Date:8/1/2014)... Recently, iFitDress.com, one of the most famous ... of top bridesmaid dresses online. At the moment, ... up to 52% off. According to the company’s senior spokesman, ... , The company’s stock is limited. Those who are ... store as soon as possible. All its products are delicately ...
(Date:8/1/2014)... the University of California, San Diego School of Medicine ... chili peppers produces chronic activation of a receptor ... reaction that ultimately reduces the risk of colorectal tumors. ... 2014 issue of The Journal of Clinical Investigation ... was originally discovered in sensory neurons, where it acts ...
(Date:8/1/2014)... York (PRWEB) August 01, 2014 Parker ... the rights of victims injured by defective medical devices ... would be recalling its Ethicon surgical power morcellator devices ... maker sited concerns involving the spread of cancer associated ... report dated July 31, 2014. , Johnson & ...
(Date:8/1/2014)... 2014 (HealthDay News) -- The U.S. Food and Drug ... drug, Jardiance, to help fight type 2 diabetes. ... to existing treatment regimens to control blood sugar levels ... director of the Office of Drug Evaluation II in ... in an agency statement. The FDA also recommended ...
(Date:8/1/2014)... New York, New York (PRWEB) August 01, 2014 ... ( http://www.gynecaremorcellatorlawsuit.com/ ) on behalf of women who allegedly ... use of power morcellators in gynecological surgeries, Bernstein Liebhard ... decision to withdraw a number of power morcellators marketed ... to a report from The New York Times, some ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 2Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 3Health News:J&J's Ethicon Unit Recalls its Power Morcellator Devices After Warnings by Federal Regulators and Concern About Risk of Spreading Occult Cancer, Parker Waichman Comments 4Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 2Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 3Health News:Morcellator Lawsuit News: Bernstein Liebhard LLP Notes Reactions to Johnson & Johnson Power Morcellator Recall 4
... MDTH ) announced today that James E. Harris has ... become the Chief,Financial Officer for Charlotte, N.C. based Coca-Cola ... years, affiliation having,served on its Board of Directors and ... until near the end of January 2008, has been,with ...
... Allscripts, the leading,provider of clinical software, connectivity ... healthcare, today announced that the company,s,TouchWorks(TM) Electronic ... 1 product,in its market segment by the ... http://www.newscom.com/cgi-bin/prnh/20061005/ALLSCRIPTSLOGO-b ), TouchWorks earned the "Best ...
... Agency Adds 23 Clients in US, Europe and ... America,s largest and,fastest growing pay-for-placement public relations agency, ... businesses from South America to Asia.,The two-year old ... in a range of industries including financial services,healthcare, ...
... Officials, Legal Experts to Discuss Latest Criminal,Cases, Decrees and ... WASHINGTON, Dec. 20 In the last year,mainstream ... than $1.9,billion in fines, civil settlements and penalties. Top ... they did not,participate in or know about the crimes., ...
... ... heart disease patients, DETROIT, Dec. 20 Studies ... depression than those without heart,disease. The link between these two diseases ... heart patients is under-recognized and,even when diagnosed, under-treated., That,s why ...
... New Site Leadership Team at Cambridge Facility -, ... of its role as the global biologics unit ... D. Skibo has joined the company,as senior vice ... of the company, has been promoted to vice ...
Cached Medicine News:Health News:James E. Harris to Become Chief Financial Officer of Coca-Cola Bottling Co. Consolidated 2Health News:Allscripts Electronic Health Record Ranked No. 1 by Physician Groups in KLAS Year-End Report 2Health News:Allscripts Electronic Health Record Ranked No. 1 by Physician Groups in KLAS Year-End Report 3Health News:PayPerClip Grows 370% in 2007 2Health News:Food and Drug Law Institute Sponsors Major Enforcement Conference 2Health News:Blue Cross Blue Shield of Michigan Foundation Funds Study Exploring Link between Heart Disease and Depression 2Health News:MedImmune Expands Scientific and Engineering Leadership 2Health News:MedImmune Expands Scientific and Engineering Leadership 3Health News:MedImmune Expands Scientific and Engineering Leadership 4Health News:MedImmune Expands Scientific and Engineering Leadership 5
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... a complete offering of cardiology catheters. Available ... catheters are designed with excellent torque, new ... better push-ability, and large inner lumens for ... 6 and 7 French sizes with pressure ...
The Compass Commander series is engineered to provide the discriminating neurosurgeon with the same capabilities offered within the commander plus+, all in a smaller, lower-cost package....
Used for access and catheterization procedures. Double flexible tipped design permits alternative use of both ends of wire guide depending upon procedural needs. Supplied sterile in peel-open package...
Medicine Products: